Cystic Fibrosis: History and Discovery

Long before anyone understood genes, salt channels, or the lungs, parents across Europe knew a grim folk sign: a baby whose forehead tasted of salt when kissed was thought to be bewitched and was not expected to live. That salty kiss — recorded in a medieval warning and again by a Spanish physician in 1606 — was, we now know, the first human recognition of cystic fibrosis. The scientific story that followed is unusually well documented and unusually fast: a clear clinical and pathological description and the name “cystic fibrosis of the pancreas” from Dorothy Hansine Andersen in 1938; the discovery that the sweat itself was abnormally salty, turning folklore into a diagnostic sweat test by 1953; the identification of the responsible gene on chromosome 7 in 1989; and, in our own century, the first drugs that fix the broken protein at its source.

The Salty Kiss: Folklore and the Earliest Recognition
Early Medical Glimpses Before 1900
Fanconi, Andersen, and the Naming of the Disease (1936–1938)
The Heat Wave and the Sweat Test (1948–1959)
What to Call It: Mucoviscidosis and the Modern Name
Finding the Gene: CFTR on Chromosome 7 (1989)
From Gene to Cure-in-Sight: CFTR Modulators
Legacy: From a Death Sentence to a Treatable Disease
Research Papers and References
Connections

The Salty Kiss: Folklore and the Earliest Recognition

The oldest trace of cystic fibrosis in the human record is not a medical text but a warning passed between parents. A folk saying preserved in northern European tradition — often quoted in the form “Woe to the child who tastes salty from a kiss on the brow, for he is cursed and soon must die” — captured, centuries before any science could explain it, the single most reliable everyday sign of the disease: a child whose skin tastes distinctly of salt. The wording above is a modern rendering of a folk tradition rather than a verbatim quotation from a single dated manuscript, and it is presented here as folklore; what is well attested is that such salty-skin warnings circulated widely in medieval and early-modern Europe and were associated with infants who failed to thrive and died young.

In the medical and magical thinking of the time, a salty brow did not suggest a disease of the sweat glands — it suggested a curse. Affected infants were commonly described as “fascinated” or “bewitched,” believed to have been marked by witches and doomed. The earliest specific printed reference along these lines is usually credited to Juan Alonso y de los Ruyzes de Fontecha, a professor at the University of Alcalá de Henares in Spain, who in 1606 wrote that when one rubs the forehead of a “bewitched” child, the fingers taste salty. The supernatural framing was wrong, but the observation underneath it was exactly right.

That is the quiet miracle of this folklore: ordinary people, working only with a kiss and a sense of taste, had identified the elevated salt of cystic fibrosis perhaps four or five centuries before a laboratory measured it. When Paul di Sant’Agnese demonstrated abnormally salty sweat in the 1950s, he did not discover something new about the body so much as supply, at last, the true explanation for a sign that frightened parents had known and dreaded for generations.

Back to Table of Contents

Early Medical Glimpses Before 1900

Between the folklore of the salty kiss and the formal description of the disease lie scattered medical glimpses, most of them autopsy findings. From the seventeenth century onward, various anatomists and physicians described children and infants who had died wasted and malnourished and whose pancreas, at post-mortem, was found to be hardened, shrunken, fibrous, or studded with cysts. Carl von Rokitansky, the great nineteenth-century Viennese pathologist, and others documented pancreatic and intestinal abnormalities in such children, and case reports through the 1800s noted the lethal combination of a diseased pancreas, foul fatty stools, failure to grow, and recurrent chest infection — the full clinical picture of cystic fibrosis, seen but not yet understood as one disease.

One striking thread concerns a condition of newborns called meconium ileus — a bowel obstruction in which the first stool is so thick and sticky it blocks the intestine. Nineteenth-century physicians described and sometimes operated on these infants without knowing why their secretions were so abnormally viscid. We now recognise meconium ileus as a classic and early manifestation of cystic fibrosis, present at birth in a meaningful minority of affected babies; it was, in effect, another piece of the disease being observed long before the whole was named.

The obstacle to recognition was conceptual, not observational. For centuries these findings were filed under whatever organ seemed most affected — a pancreatic disease here, a bowel obstruction there, a chronic chest complaint elsewhere, very often lumped together with celiac disease, which shares the malnutrition and fatty stools. The leap that remained to be made was to see that one underlying disorder could damage the pancreas, the lungs, the bowel, and the sweat glands all at once. That synthesis arrived in the 1930s.

Back to Table of Contents

Fanconi, Andersen, and the Naming of the Disease (1936–1938)

The disease was pulled into focus over a span of just a few years on two continents. In 1936, the Swiss paediatrician Guido Fanconi, working at the University Children’s Hospital in Zürich, published a short report (with co-authors) describing two children whose autopsies showed congenital cystic and fibrotic change of the pancreas together with bronchiectasis — chronically widened, infection-prone airways. His German title is usually rendered as “Das Coeliaksyndrom bei angeborener zystischer Pankreasfibromatose und Bronchiektasien” (the coeliac syndrome with congenital cystic pancreatic fibromatosis and bronchiectasis). Fanconi is widely credited with being the first to link the pancreatic and lung findings as one congenital entity and with introducing language — cystic fibromatosis of the pancreas — close to the name that would stick. Some historians read his 1936 wording as the first use of the term “cystic fibrosis” itself; what is not disputed is that his report was an early and pivotal recognition of the combined syndrome.

The definitive description, however, came two years later and an ocean away. In 1938, the American pathologist Dorothy Hansine Andersen, working at Babies Hospital of the Columbia-Presbyterian Medical Center in New York, published the landmark paper “Cystic Fibrosis of the Pancreas and Its Relation to Celiac Disease: A Clinical and Pathologic Study” in the American Journal of Diseases of Children. Drawing on a large series of autopsies — on the order of four to five dozen cases — Andersen did what no one before her had done: she separated these children cleanly from the broad, ill-defined category of “celiac disease,” demonstrated that they shared a single consistent pattern of pancreatic, intestinal, and pulmonary disease, established it as a distinct clinical and pathological entity, and gave it the name by which it is still known: cystic fibrosis of the pancreas. It is for this reason that Andersen is generally credited as the person who first clearly described and named the disease.

It is worth pausing on who Andersen was, because her achievement came against real resistance. A woman in a field that largely excluded women, she had been told that a career in surgery was effectively closed to her and instead built a towering career in pathology and paediatrics. She not only delineated cystic fibrosis but went on to recognise its inheritance as a recessive trait, to help devise diagnostic criteria, and to mentor the next generation of CF researchers — including the physician whose heat-wave observation comes next in this story. Fanconi and Andersen are best understood together: Fanconi first connected the pancreas and the lungs; Andersen, with the weight of a large autopsy series behind her, defined the disease and named it.

Back to Table of Contents

The Heat Wave and the Sweat Test (1948–1959)

The next breakthrough turned the ancient salty-kiss folklore into hard laboratory medicine, and it began with the weather. During a severe heat wave in New York City in the summer of 1948 (with further cases the following summer), the paediatrician Paul di Sant’Agnese — a colleague of Andersen at the same New York institution — noticed that an unusual number of his cystic fibrosis patients were arriving in the hospital severely dehydrated and prostrate from the heat, far more so than other children. Reasoning that they were somehow losing too much salt, and reportedly struck by a chalky salt residue left on a glass a patient had drunk from, he set out to measure the electrolyte content of their sweat directly.

What he found was dramatic and consistent. In a series of 43 patients with cystic fibrosis, the concentrations of sodium and chloride in sweat were roughly two to four times higher than in unaffected people. This was the first major mechanistic advance in the disease since Andersen named it: it explained the heat-wave collapses, it explained the centuries-old salty kiss, and — crucially — it offered something the field had never had, an objective and relatively simple test for the disease in a living child. The findings were published by di Sant’Agnese and colleagues in 1953 in the journal Pediatrics (“Abnormal Electrolyte Composition of Sweat in Cystic Fibrosis of the Pancreas”).

Measuring sweat reliably, however, still required a safe and standardised method. That arrived in 1959, when Lewis Gibson and Robert Cooke introduced pilocarpine iontophoresis: a tiny, painless electric current drives the drug pilocarpine into a patch of skin, stimulating the sweat glands locally so the sweat can be collected and its chloride measured. The Gibson–Cooke quantitative pilocarpine iontophoresis sweat test became, and remains to this day, the gold-standard diagnostic test for cystic fibrosis — one of the rare instances in medicine where a folk observation, a clinical insight, and a precise laboratory technique line up across the centuries to point at the very same thing.

Back to Table of Contents

What to Call It: Mucoviscidosis and the Modern Name

Andersen had named the disease for what she saw down a microscope: a pancreas turned cystic and fibrous. But as understanding deepened, it became clear that the pancreas was only one casualty, and arguably not the most important one. The thread running through every affected organ — the clogged pancreatic ducts, the obstructed newborn bowel, and above all the lungs choked with tenacious mucus — was abnormally thick, sticky secretions. In 1943, the American pathologist Sydney Farber proposed the alternative name mucoviscidosis (literally, “thick-mucus condition”) to emphasise that the disorder was fundamentally one of viscid mucus affecting many exocrine glands, not merely a disease of the pancreas.

For decades both names coexisted: “mucoviscidosis” was especially favoured in continental Europe, while “cystic fibrosis” predominated in the English-speaking world, and the term is still encountered in several languages today. Over time the English name — usually shortened simply to cystic fibrosis, or CF — became the international standard, even though “mucoviscidosis” arguably described the underlying problem more accurately. The naming debate matters historically because it tracks the shift in understanding: from a disease defined by the appearance of one organ to a disease understood as a body-wide failure of secretion.

That shift would only be completed when the molecular cause was found. The thick secretions, the salty sweat, the pancreatic and lung damage — all of them, it turned out, trace back to a single malfunctioning protein that normally moves chloride (and water) across the surfaces of cells. Naming the disease had taken from folklore to 1938; explaining it at the level of a single molecule would take another half-century.

Back to Table of Contents

Finding the Gene: CFTR on Chromosome 7 (1989)

Through the mid-twentieth century it was established that cystic fibrosis is inherited in an autosomal recessive pattern — a child must receive a faulty copy of the same gene from both parents — but no one knew which gene, where it sat, or what it did. The hunt to find it became one of the defining quests of early human genetics. By the mid-1980s, work led by Lap-Chee Tsui at the Hospital for Sick Children in Toronto had linked the disease to genetic markers on chromosome 7, narrowing the search to a particular neighbourhood of the genome but not yet to the gene itself.

Pinning down the actual gene required a technically heroic approach known as positional cloning — identifying a gene from its map location alone, without knowing in advance what protein it made or what it did. Using the painstaking techniques of “chromosome walking and jumping” to traverse hundreds of thousands of DNA base pairs, a transatlantic collaboration between Tsui’s group, the biochemist John R. Riordan, and Francis S. Collins’s laboratory (then at the University of Michigan) isolated the gene in 1989. Their results appeared in a celebrated series of papers in the journal Science that year. They named the gene’s product the cystic fibrosis transmembrane conductance regulator, or CFTR — a channel that ferries chloride ions across cell membranes, exactly the machinery whose failure produces salty sweat and thick mucus.

The same work pinpointed the single most common disease-causing mutation, a three-base-pair deletion that removes one amino acid (a phenylalanine) at position 508 of the protein, written ΔF508 (delta-F508, also called F508del). This one mutation accounts for roughly two-thirds of cystic fibrosis chromosomes worldwide, though more than a thousand other CFTR mutations have since been catalogued. The discovery was a landmark twice over: it gave cystic fibrosis a precise molecular cause and enabled genetic testing and carrier screening, and it served as a celebrated proof-of-principle for positional cloning that helped pave the way for the Human Genome Project — a project Francis Collins would later go on to lead.

Back to Table of Contents

From Gene to Cure-in-Sight: CFTR Modulators

Finding the gene in 1989 raised an obvious and agonising hope: if the problem is one broken protein, could a drug be made to fix it? For more than two decades the honest answer was “not yet.” In the meantime, care for cystic fibrosis improved enormously through means that did not touch the underlying defect — airway-clearance physiotherapy, inhaled mucus-thinning and antibiotic treatments, aggressive nutrition with pancreatic enzyme replacement, and specialised CF centres — and these advances steadily pushed median survival upward from early childhood toward, and then well into, adulthood. But the goal of treating the root cause remained out of reach.

It was finally realised on 31 January 2012, when the U.S. Food and Drug Administration approved ivacaftor (brand name Kalydeco, developed by Vertex Pharmaceuticals), the first drug to treat the underlying molecular defect rather than its downstream consequences. Ivacaftor is a CFTR potentiator: it works on CFTR protein that does reach the cell surface but stays shut, holding the channel open longer so chloride can flow. Its initial approval was for patients carrying the G551D mutation — a so-called gating mutation present in only about 4–5% of people with CF — but in that group the results were striking, with marked improvements in lung function and weight, and it established the entirely new category of CFTR modulator therapy.

The years since have brought combination modulators that help the far more common ΔF508 mutation, in which the protein is misfolded and largely fails to reach the cell surface at all. Drugs called correctors (such as lumacaftor, tezacaftor, and elexacaftor) help the protein fold and traffic correctly, and are paired with the potentiator ivacaftor. The triple combination elexacaftor–tezacaftor–ivacaftor, approved in the United States in 2019, is effective for the large majority of people with cystic fibrosis and has been described as transformative. These drugs are not a cure — they do not correct the gene itself, must be taken continuously, are extremely expensive, and do not help every mutation — but they treat the disease at its source, the long-sought achievement first made imaginable by the gene discovery of 1989.

Back to Table of Contents

Legacy: From a Death Sentence to a Treatable Disease

The arc of this history is one of the most encouraging in modern medicine. When Dorothy Andersen named cystic fibrosis in 1938, it was a disease of infancy and early childhood; most affected children died very young, and a diagnosis was understood as a death sentence. Within a single long human lifetime, the disease has been described and named, given an objective diagnostic test, traced to a specific gene on a specific chromosome, and at last attacked with drugs aimed at the broken protein itself. Median survival, once measured in a few years, is now measured in decades, and a growing population of adults lives with CF — a reality that would have seemed impossible to the parents who feared the salty kiss.

What gives the story its shape is the way each chapter answered the one before. Folklore noticed the salt; di Sant’Agnese explained the salt and made it measurable; the 1989 gene discovery explained why the sweat is salty and the mucus thick, by revealing the faulty chloride channel beneath both; and the CFTR modulators of the 2010s set out to repair that very channel. It is a near-unbroken line from a medieval mother’s kiss to a twenty-first-century pharmacy — the same disease, seen ever more deeply, until at last it could be reached.

The honest coda is that the work is unfinished. Modulator drugs do not help every mutation, are unevenly available around the world because of cost, and manage rather than cure the condition; research continues toward gene-directed and mutation-agnostic therapies that might one day finish what 1989 began. But for a disorder that was, for most of human history, simply a curse to be wept over, the trajectory from the salty kiss to ivacaftor stands as a powerful demonstration of what careful observation, persistent science, and a refusal to accept “incurable” can achieve.

Back to Table of Contents

Research Papers and References

The references below combine the landmark primary publications in the history of cystic fibrosis — Andersen’s 1938 description, di Sant’Agnese’s 1953 sweat-electrolyte paper, and the 1989 Science reports identifying the CFTR gene — with curated PubMed topic-search links into the historical and biographical literature. Real DOIs and PMIDs are given where confidently confirmed; broader historical topics are provided as PubMed searches. Each external link opens in a new tab.

Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. American Journal of Diseases of Children. 1938;56(2):344-399. (Landmark first clear description and naming of the disease.) — PubMed: Andersen 1938 description of cystic fibrosis
di Sant’Agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas: clinical significance and relationship to the disease. Pediatrics. 1953;12(5):549-563. (PMID 13111855.) — doi:10.1542/peds.12.5.549
Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066-1073. — doi:10.1126/science.2475911
Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059-1065. — doi:10.1126/science.2772657
Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-1080. — doi:10.1126/science.2570460
Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23(3):545-549. — PubMed: Gibson–Cooke 1959 sweat test
Fanconi G — first association of cystic pancreatic fibromatosis with bronchiectasis (1936, Zürich); history and the early naming of cystic fibrosis — PubMed: Fanconi and the early history of cystic fibrosis
Dorothy Hansine Andersen — biography and her role in describing and naming cystic fibrosis — PubMed: Dorothy Andersen biography and legacy
Paul di Sant’Agnese, the 1948 heat-wave observation, and the discovery of the sweat abnormality — PubMed: di Sant’Agnese and the sweat-test history
History of cystic fibrosis — from the salty-kiss folklore and bewitched children to modern diagnosis — PubMed: history of cystic fibrosis and the salty kiss
Positional cloning of the CFTR gene on chromosome 7 — Tsui, Riordan, Collins, and the ΔF508 mutation — PubMed: CFTR gene discovery and ΔF508
Farber S — mucoviscidosis and the concept of a generalised disorder of mucus-secreting glands (1943) — PubMed: Farber, mucoviscidosis, and the naming debate
Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New England Journal of Medicine. 2011;365(18):1663-1672. (Pivotal ivacaftor trial.) — doi:10.1056/NEJMoa1105185
CFTR modulator therapy — ivacaftor (2012) and the elexacaftor–tezacaftor–ivacaftor combination: treating the underlying defect — PubMed: CFTR modulators and modern CF therapy

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents